Skip to main content
×
Home
    • Aa
    • Aa

Cholesterol-lowering efficacy of a microencapsulated bile salt hydrolase-active Lactobacillus reuteri NCIMB 30242 yoghurt formulation in hypercholesterolaemic adults

  • Mitchell L. Jones (a1) (a2), Christopher J. Martoni (a2), Mathieu Parent (a2) and Satya Prakash (a1)
Abstract

Several studies have reported limited or no reduction in serum cholesterol in response to probiotic formulations. Recently, probiotics have shown promise in treating metabolic disease due to improved strain selection and delivery technologies. The aim of the present study was to evaluate the cholesterol-lowering efficacy of a yoghurt formulation containing microencapsulated bile salt hydrolase (BSH)-active Lactobacillus reuteri NCIMB 30242, taken twice per d over 6 weeks, in hypercholesterolaemic adults. A total of 114 subjects completed this double-blind, placebo-controlled, randomised, parallel-arm, multi-centre study. This interventional study included a 2-week washout, 2-week run-in and 6-week treatment period. Subjects were randomised to consume either yoghurts containing microencapsulated L. reuteri NCIMB 30242 or placebo yoghurts. Over the intervention period, subjects consuming yoghurts containing microencapsulated L. reuteri NCIMB 30242 attained significant reductions in LDL-cholesterol (LDL-C) of 8·92 % (P = 0·016), total cholesterol (TC) of 4·81 % (P = 0·031) and non-HDL-cholesterol (HDL-C) of 6·01 % (P = 0·029) over placebo, and a significant absolute change in apoB-100 of − 0·19 mmol/l (P = 0·049). Serum concentrations of TAG and HDL-C were unchanged over the course of the study. Present results show that consumption of microencapsulated BSH-active L. reuteri NCIMB 30242 yoghurt is efficacious and safe for lowering LDL-C, TC, apoB-100 and non-HDL-C in hypercholesterolaemic subjects. The efficacy of microencapsulated BSH-active L. reuteri NCIMB 30242 yoghurts appears to be superior to traditional probiotic therapy and akin to that of other cholesterol-lowering ingredients.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Cholesterol-lowering efficacy of a microencapsulated bile salt hydrolase-active Lactobacillus reuteri NCIMB 30242 yoghurt formulation in hypercholesterolaemic adults
      Available formats
      ×
      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your Dropbox account. Find out more about sending content to Dropbox.

      Cholesterol-lowering efficacy of a microencapsulated bile salt hydrolase-active Lactobacillus reuteri NCIMB 30242 yoghurt formulation in hypercholesterolaemic adults
      Available formats
      ×
      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your Google Drive account. Find out more about sending content to Google Drive.

      Cholesterol-lowering efficacy of a microencapsulated bile salt hydrolase-active Lactobacillus reuteri NCIMB 30242 yoghurt formulation in hypercholesterolaemic adults
      Available formats
      ×
Copyright
Corresponding author
*Corresponding author: Dr S. Prakash, fax: +1 514 398 7461, email satya.prakash@mcgill.ca
Linked references
Hide All

This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.

1 National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) (2002) Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106, 31433421.

2SM Grundy , JI Cleeman , CNB Merz , (2004) Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110, 227239.

3P Durrington (2003) Dyslipidaemia. Lancet 362, 717731.

4CJ Murray & AD Lopez (1997) Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 349, 14361442.

5World Health Organization (2002) The World Health Report 2002 – Reducing Risks, Promoting Healthy Life. Geneva: WHO.

6TA Jacobson (2000) ‘The lower the better’ in hypercholesterolemia therapy: a reliable clinical guideline? Ann Intern Med 133, 549554.

8C Stancu & A Sima (2001) Statins: mechanism of action and effects. J Cell Mol Med 5, 378387.

11G Schaafsma , WJ Meuling , W van Dokkum , (1998) Effects of a milk product, fermented by Lactobacillus acidophilus and with fructo-oligosaccharides added, on blood lipids in male volunteers. Eur J Clin Nutr 52, 436440.

12MC Bertolami , AA Faludi & M Batlouni (1999) Evaluation of the effects of a new fermented milk product (Gaio) on primary hypercholesterolemia. Eur J Clin Nutr 53, 97101.

13M Agerbaek , LU Gerdes & B Richelsen (1995) Hypocholesterolemic effect of a new fermented milk product in healthy middle-aged men. Eur J Clin Nutr 49, 346352.

14L Agerholm-Larsen , A Raben & N Haulrik (2000) Effect of 8 week intake of probiotic milk products on risk factors for cardiovascular diseases. Eur J Clin Nutr 54, 288297.

16NM de Roos , G Schouten & MB Katan (1999) Yoghurt enriched with Lactobacillus acidophilus does not lower blood lipids in healthy men and women with normal to borderline high serum cholesterol levels. Eur J Clin Nutr 53, 277280.

17KA Greany , MJ Bonorden , JM Hamilton-Reeves , (2008) Probiotic capsules do not lower plasma lipids in young women and men. Eur J Clin Nutr 62, 232237.

18SJ Lewis & S Burmeister (2005) A double-blind placebo-controlled study of the effects of Lactobacillus acidophilus on plasma lipids. Eur J Clin Nutr 59, 776780.

19SY Lin , JW Ayres , L Winkler Jr, (1989) Lactobacillus effects on cholesterol: in vitro and in vivo results. J Dairy Sci 72, 28852899.

20WB Branton , ML Jones , C Tomaro-Duchesneau , (2011) In vitro characterization and safety of the probiotic strain Lactobacillus reuteri cardioviva NCIMB 30242. Int J Probiotics Prebiotics 6, 112.

21MP Taranto , F Sesma , APD Holgado , (1997) Bile salts hydrolase plays a key role on cholesterol removal by Lactobacillus reuteri. Biotechnol Lett 19, 845847.

22I De Smet , L Van Hoorde , M De Saeyer , (1994) In vitro study of bile salt hydrolase (BSH) activity of BSH isogenic Lactobacillus plantarum 80 strains and estimation of cholesterol lowering through enhanced BSH activity. Microb Ecol Health Dis 7, 315329.

23I De Smet , L Van Hoorde , WM Vande , (1995) Significance of bile salt hydrolytic activities of lactobacilli. J Appl Bacteriol 79, 292301.

24MH Davidson (2008) Interrupting bile-acid handling and lipid and glucose control: effects of colesevelam on glucose levels. J Clin Lipid 2, S29S33.

25BJ Johnson , JY Lee , A Pickert , (2010) Bile acids stimulate ATP hydrolysis in the purified cholesterol transporter ABCG5/G8. Biochemistry 49, 34033411.

26C Thomas , R Pellicciari , M Pruzanski , (2008) Targeting bile-acid signalling for metabolic diseases. Nat Rev Drug Discov 7, 678693.

27M Watanabe , SM Houten , C Mataki , (2006) Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature 439, 484489.

28WH Holzapfel , P Haberer , J Snel , (1998) Overview of gut flora and probiotics. Int J Food Microbiol 41, 85101.

29Y Huang & MC Adams (2004) In vitro assessment of the upper gastrointestinal tolerance of potential probiotic dairy propionibacteria. Int J Food Microbiol 91, 253260.

30TMS Chang (2005) Therapeutic applications of polymeric artificial cells. Nature Rev Drug Discov 4, 221235.

31R Gugerli , E Cantana , C Heinzen , (2002) Quantitative study of the production and properties of alginate/poly-l-lysine microcapsules. J Microencapsul 19, 571590.

33C Martoni , J Bhathena , ML Jones , (2007) Investigation of microencapsulated BSH active Lactobacillus in the simulated human GI tract. J Biomed Biotechnol 2007, 13684.

34C Martoni , J Bhathena , AM Urbanska , (2008) Microencapsulated bile salt hydrolase producing Lactobacillus reuteri for oral targeted delivery in the gastrointestinal tract. Appl Microbiol Biotechnol 81, 225233.

35J Bhathena , C Martoni , A Kulamarva , (2009) Orally delivered microencapsulated live probiotic formulation lowers serum lipids in hypercholesterolemic hamsters. J Med Food 12, 310319.

36AK Batta , G Salen , P Batta , (2002) Simultaneous quantitation of fatty acids, sterols and bile acids in human stool by capillary gas-liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci 775, 153161.

37TC Andrews , CM Ballantyne , JA Hsia , (2001) Achieving and maintaining national cholesterol education program low-density lipoprotein cholesterol goals with five statins. Am J Med 111, 185191.

38I Demonty , RT Ras , HC van der Knaap , (2009) Continuous dose-response relationship of the LDL-cholesterol-lowering effect of phytosterol intake. J Nutr 139, 271284.

40R Hou & AC Goldberg (2009) Lowering low-density lipoprotein cholesterol: statins, ezetimibe, bile acid sequestrants, and combinations: comparative efficacy and safety. Endocrinol Metab Clin North Am 38, 7997.

41C Gagne , D Gaudet & E Bruckert (2002) Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation 105, 24692475.

42RE Ostlund Jr (2004) Phytosterols and cholesterol metabolism. Curr Opin Lipidol 15, 3741.

44LG Ooi , R Ahmad , KH Yuen , (2010) Lactobacillus acidophilus CHO-220 and inulin reduced plasma total cholesterol and low-density lipoprotein cholesterol via alteration of lipid transporters. J Dairy Sci 93, 50485058.

45J Jeun , S Kim , SY Cho , (2010) Hypocholesterolemic effects of Lactobacillus plantarum KCTC3928 by increased bile acid excretion in C57BL/6 mice. Nutrition 26, 321330.

47P Lepercq , P Relano , C Cayuela , (2004) Bifidobacterium animalis strain DN-173 010 hydrolyses bile salts in the gastrointestinal tract of pigs. Scand J Gastroenterol 39, 12661271.

48P Marteau , E Cuillerier , S Meance , (2002) Bifidobacterium animalis strain DN-173 010 shortens the colonic transit time in healthy women: a double-blind, randomized, controlled study. Aliment Pharmacol Ther 16, 587593.

49M Begley , C Hill & CGM Gahan (2006) Bile salt hydrolase activity in probiotics. Appl Environ Microbiol 72, 17291738.

50ER Schiff , NC Small & JM Dietschy (1972) Characterization of the kinetics of the passive and active transport mechanisms for bile acid absorption in the small intestine and colon of the rat. J Clin Invest 51, 13511362.

51PM Ridker , RJ Glynn & CH Hennekens (1998) C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation 97, 20072011.

52PM Ridker , CH Hennekens , JE Buring , (2000) C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 342, 836843.

53PM Ridker , N Rifai , M Clearfield , (2001) Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 344, 19591965.

54PM Ridker , MJ Stampfer & N Rifai (2001) Novel risk factors for systemic atherosclerosis – a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 285, 24812485.

55WL Roberts (2004) CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease – Application to Clinical and Public Health Practice – Laboratory tests available to assess inflammation performance and standardization – A background paper. Circulation 110, E572E576.

Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

British Journal of Nutrition
  • ISSN: 0007-1145
  • EISSN: 1475-2662
  • URL: /core/journals/british-journal-of-nutrition
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Keywords:

Type Description Title
WORD
Supplementary Materials

Jones Supplementary Appendix
Jones Supplementary Appendix

 Word (148 KB)
148 KB